



Príomhoifigeach Cliniúil  
Oifig an Phríomhoifigigh Cliniúil

Ospidéal Dr Steevens, Lána Steevens  
Baile Átha Cliath 8 , D08 W2A8

Chief Clinical Officer  
Office of the Chief Clinical Officer

Dr Steevens Hospital, Steevens Lane  
Dublin 8, D08 W2A8

[www.hse.ie](http://www.hse.ie)  
[@hselive](https://twitter.com/hselive)

t 01 635 2000  
e [cco@hse.ie](mailto:cco@hse.ie)

**BY EMAIL ONLY**

Deputy Mark Ward  
Dáil Éireann  
Leinster House  
Kildare Street  
Dublin 2

2<sup>nd</sup> July 2024

**PQ24656/24- Deputy Mark Ward- To ask the Minister for Health if brincidofovir can be used alongside a bone marrow transplant treatment; how patients can apply for this; and if he will make a statement on the matter.**

Dear Deputy Ward,

Thank you for your representation.

Brincidofovir received an orphan designation status with the EMA for the prevention of cytomegalovirus and for the treatment of smallpox. It also appears to be under a paediatric investigation plan for the treatment of smallpox [EMEA-001904-PIP03-18-M02 - paediatric investigation plan | European Medicines Agency \(europa.eu\)](#)

The decision as to whether this can be prescribed for a patient alongside their bone marrow transplant treatment is a clinical decision by their consultant and is individual to each patient. In addition, as this product is in the EMA process, it wouldn't be considered for reimbursement in the absence of a formal pricing and reimbursement application by the Marketing Authorisation Holder to the HSE Corporate Pharmaceutical Unit.

I hope this provides you with some assistance and answers your question.

Yours sincerely

---

Sharon Hayden  
General Manager  
Office of the Chief Clinical Officer